Form D · Biotechnology
Acenxion Biosytems, Inc.
Lawrence, KS · CIK 0001974107
Offering snapshot reported Aug 14, 2024 · SEC filing
- Reported sold
- $1.07M Offering amount: $1.07M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Jul 19, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 14, 2024 | Initial | $1,070,000 | No comparison | 5 | SEC filing |
| Apr 18, 2023 | Initial | $50,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-521517
$270,000 of the offering was issued upon the conversion of SAFEs.
Source: Form D, filed Aug 14, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Wayne Carter | Director |
| Howard Goldstein | Director |
| Brian Struchtemeyer | Director, Executive |
| Roy Swiger | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2029 Becker Drive Suites 225 & 227
Lawrence, KS, 66047
Lawrence, KS, 66047